



STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W., SUITE 600 WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540; (202) 371-6566

ROBERT GREENE STERNE EDWARD J. KESSLER JORGE A. GOLDSTEIN SAMUEL L. FOX DAVID K.S. CORNWELL ROBERT W. ESMOND TRACY-GENE G. DURKIN MICHELE A. CIMBALA MICHAEL B. RAY ROBERT E. SOKOHL

ERIC K. STEFFE MICHAEL Q. LEE STEVEN R. LUDWIG JOHN M. COVERT* RAZ E. FLESHNER ROBERT C. MILLONIG MICHAEL V. MESSINGER JUDITH U. KIM TIMOTHY J. SHEA, JR.

DONALD R. MCPHAIL PATRICK E. GARRETT STEPHEN G. WHITESIDE NOEL B. WHITLEY JEFFREY T. HELVEY HEIDI L. KRAUS JEFFREY R. KURIN RAYMOND MILLIEN PATRICK D. O'BRIEN BRIAN S. ROSENBLOOM

LAWRENCE B. BUGAISKY CRYSTAL D. SAYLES EDWARD W. YEE ALBERT L. FERRO* DONALD R. BANOWIT* PETER A. JACKMAN* MOLLY A. MCCALL* TERESA U. MEDLER* JEFFREY S. WEAVER

DONALD J. FEATHERSTONE **
KAREN R. MARKOWICZ**
GRANT E. REED**
SUZANNE E. ZISKA** BRIAN J. DEL BUONO" CAMERON H. TOUSI** VINCENT L. CAPUANO**

ROBERT H. BENSON OF COUNSEL

*BAR OTHER THAN D.C. **REGISTERED PATENT AGENTS

May 27, 1999

WRITER'S DIRECT NUMBER: (202) 371-2625

INTERNET ADDRESS: ESTEFFE@SKGF.COM

Assistant Commissioner for Patents Washington, D.C. 20231

JUN 1

But the section of th

MATRIX CLUTTER PRINTER DERVICE CENTER

U.S. Utility Patent Application Re:

Appl. No. 08/935,377; Filed: September 22, 1997

T Cells Specific for Target Antigens and Vaccines Based Thereon For: Inventors: Zauderer, M.

Our Ref: 1821.0010000/EKS/CMB

Sir:

÷

Transmitted herewith for appropriate action are the following documents:

- Petition Extension of Time Under 37 C.F.R. § 1.136(a)(1) (in duplicate); 1.
- Letter and Reply Concerning Notice to Comply With Requirements for Patent 2. Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- 3. Copy of Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- Copy of postcard date stamped May 10, 1999 by the U.S. Patent and Trademark 4.

STERNE. KESSLER. GOLDSTEIN & FOX P.L.L.C.

Assistant Commissioner for Patents May 27, 1999 Page 2

- 5. Our Check No. <u>24497</u> in the amount of \$55.00 to cover the fee for a one month extension of time; and
- 6. A return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe

Attorney for Applicant Registration No. 36,688

Enclosures

P:\USERS\CBOUCHEZ\1821\1821001not.cvr SKGF Rev. 9/23/98 dcw



Applicant: Zauderer, M.

Application No.: 08/935,377

Filed: September 22, 1997

MAY 1 B 1999 S

Due Date: None

Art Unit: 1643

Examiner: To be assigned

Docket: 1821.0010000

Atty: EKS/CMB

For: T Cells Specific for Target Antigens and Vaccines Based Thereon

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

Transmittal letter (in duplicate);

Preliminary Amendment and Submission of Sequence Listing; Paper and computer readable copy of Sequence Listing; Change of Correspondence Address;

Power of Attorney from Assignee; and Certificate Under 37 C.F.R. § 3.73(b).

Please Date Stamp And Return To Our Courier

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Zauderer, M.

Appl. No. 08/935,377

Filed: September 22, 1997

For:

T Cells Specific for Target Antigens

and Vaccines Based Thereon

Art Unit:

1618

Examiner:

Wessendorf, T.

Atty. Docket: 1821.0010000/EKS/CMB

Letter and Reply Concerning Notice to Comply With **Requirements for Patent Applications Containing** Nucleotide and/or Amino Acid Sequence Disclosures

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

As the accompanying copy postcard indicates, Applicant filed the sequence listing for the above-identified application on May 10, 1999. Because Applicant has changed representation, the Notice did not come to the attention of the undersigned until May 20, 1999; and therefore, Applicant did not submit the Petition for Extension of Time at the time of filing the sequence listing.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe

Attorney for Applicant

Registration No. 36,688

1100 New York Avenue, N.W. Suite 600

Washington, D.C. 20005-3934

(202) 371-2600

P:\USERS\CBOUCHEZ\1821\001\lett.wpd SKGF1/25/98 dcw







Application No. 28/93537/

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
X	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
X	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Applicant Must Provide:	
X	An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X For	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). The questions regarding compliance to these requirements, please contact:
Fo	r Rules Interpretation, call (703) 308-4216
Fo	r CRF Submission Help, call (703) 308-4212
. 0	r Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE